← Back to headlines
Celltrion's Truxima leads U.S. prescription market in February
Celltrion's biosimilar drug, Truxima, has been reported as the market leader in the U.S. prescription market for February.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
